Spruce Biosciences to wind down investment for genetic disorder drug
Portfolio Pulse from
Spruce Biosciences announced it will wind down investments in its genetic disorder drug after failing to meet the primary endpoint in a mid-stage study.
December 10, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Spruce Biosciences is ceasing investment in its genetic disorder drug following unsuccessful mid-stage study results.
The decision to wind down investments in the drug is likely to negatively impact Spruce Biosciences' stock price as it indicates a setback in their product pipeline. Investors may react negatively to the failure in the study, leading to a potential decrease in stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100